GlassScriptPhysician profile
David Keith Bridgers
NPI 1982696829
$5,999.37
in general payments reported to CMS, 2019-2025
51 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $694 · 2021: $1,120 · 2022: $1,060 · 2023: $882 · 2024: $712 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $543.03 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $509.64 | 2019-2025 | Vraylar, Qulipta, Dalvance |
| Amgen INC. | $410.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $299.74 | 2023-2025 | Sunosi, Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.31 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $253.17 | 2021-2024 | |
| Esperion Therapeutics, INC. | $223.55 | 2020-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $223.09 | 2022-2025 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $195.51 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $194.14 | 2019-2023 | |
| Amarin Pharma, INC. | $178.78 | 2019-2022 | |
| Lilly USA, LLC | $165.34 | 2019-2025 | Jardiance, Zepbound |
| Arbor Pharmaceuticals, INC. | $162.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.07 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bridgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.